These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27046542)

  • 1. The impact of early human data on clinical development: there is time to win.
    Swart P; Lozac'h F; Simon M; van Duijn E; Vaes WH
    Drug Discov Today; 2016 Jun; 21(6):873-9. PubMed ID: 27046542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of cAMS for
    Lozac'h F; Fahrni S; Maria D; Welte C; Bourquin J; Synal HA; Pearson D; Walles M; Camenisch G
    Bioanalysis; 2018 Mar; 10(5):321-339. PubMed ID: 29451392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mini-Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME Study.
    Spracklin DK; Chen D; Bergman AJ; Callegari E; Obach RS
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):428-434. PubMed ID: 32562380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of accelerator mass spectrometry to obtain early human ADME/PK data.
    Lappin G; Garner RC
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):23-31. PubMed ID: 16922650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers.
    Sarapa N; Hsyu PH; Lappin G; Garner RC
    J Clin Pharmacol; 2005 Oct; 45(10):1198-205. PubMed ID: 16172185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerator mass spectrometry in pharmaceutical research and development--a new ultrasensitive analytical method for isotope measurement.
    Garner RC
    Curr Drug Metab; 2000 Sep; 1(2):205-13. PubMed ID: 11465084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.
    Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Brian Houston J; Oosterhuis B; Bjerrum OJ; Grynkiewicz G; Alder J; Rowland M; Garner C
    Eur J Pharm Sci; 2011 Jun; 43(3):141-50. PubMed ID: 21540108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of low background liquid scintillation counter for non-clinical ADME studies.
    Onishi A; Kogame A; Tagawa Y; Kondo T; Asahi S
    Xenobiotica; 2013 Jun; 43(6):520-6. PubMed ID: 23256624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic analysis of 14C-ursodiol in newborn infants using accelerator mass spectrometry.
    Gordi T; Baillie R; Vuong le T; Abidi S; Dueker S; Vasquez H; Pegis P; Hopper AO; Power GG; Blood AB
    J Clin Pharmacol; 2014 Sep; 54(9):1031-7. PubMed ID: 24805288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches.
    Beaumont C; Young GC; Cavalier T; Young MA
    Br J Clin Pharmacol; 2014 Dec; 78(6):1185-200. PubMed ID: 25041729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coupling of UHPLC with fast fraction collection-microplate scintillation counting and MS for radiolabeled metabolite profiling.
    Tong W; Chowdhury S; Wrona M; Bateman K
    Bioanalysis; 2012 Jun; 4(11):1299-309. PubMed ID: 22720649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
    Nassar AE; Talaat RE; Kamel AM
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics.
    Lappin G; Stevens L
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1021-33. PubMed ID: 18680438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
    Lappin G; Seymour M
    Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom.
    Barker J; Garner RC
    Rapid Commun Mass Spectrom; 1999; 13(4):285-93. PubMed ID: 10097404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity-based analytical approaches to support human absolute bioavailability studies.
    Xu XS; Jiang H; Christopher LJ; Shen JX; Zeng J; Arnold ME
    Bioanalysis; 2014 Feb; 6(4):497-504. PubMed ID: 24568352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
    Garner RC
    Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerator MS: its role as a frontline bioanalytical technique.
    Seymour MA
    Bioanalysis; 2011 Dec; 3(24):2817-23. PubMed ID: 22185281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microdose pharmacogenetic study of ¹⁴C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9∗3 on its pharmacokinetics and metabolism.
    Ikeda T; Aoyama S; Tozuka Z; Nozawa K; Hamabe Y; Matsui T; Kainuma M; Hasegawa S; Maeda K; Sugiyama Y
    Eur J Pharm Sci; 2013 Jul; 49(4):642-8. PubMed ID: 23727057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding value through accelerator mass spectrometry-enabled first in human studies.
    Seymour MA
    J Labelled Comp Radiopharm; 2016 Dec; 59(14):640-647. PubMed ID: 27444819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.